The weekly litigation news digest is live. Subscribe now
Methods For Treating Hepcidin-Mediated Disorders - EP3329018
The patent EP3329018 was granted to Astrazeneca Pharmaceuticals on Mar 31, 2021. The application was originally filed on Jul 28, 2016 under application number EP16833574A. The patent is currently recorded with a legal status of "Revoked".
EP3329018
- Application Number
- EP16833574A
- Filing Date
- Jul 28, 2016
- Status
- Revoked
- Nov 23, 2024
- Publication Date
- Mar 31, 2021
- External Links
- Slate, Register, Google Patents
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (2) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents